Hepatology Acceptance Rate

AASLD does not publish a stable official acceptance rate for Hepatology. The AASLD journals page describes the editorial scope and companion journals but omits acceptance-rate data.

Third-party aggregators report estimates around 15%. That is directionally useful - this is clearly a selective liver journal - but the specific number varies by source and should not be treated as precise.

What is stable is the editorial posture:

• the journal is the AASLD flagship, covering all aspects of liver biology and disease
• viral hepatitis, MASLD/MASH, hepatocellular carcinoma, liver transplantation, and cholestatic diseases are core areas
• the editorial team values both clinical and translational work, but with clear disease relevance
• the companion journal Hepatology Communications (IF ~4.6) absorbs sound work below the flagship bar

That is the planning surface authors actually need.

At triage, the editor is usually asking:

• does this study advance understanding or management of a liver disease?
• is the evidence strong enough - large cohorts, mechanistic depth, or clinical validation?
• does the work address a question the hepatology community considers important now?
• would this paper change clinical practice, disease classification, or treatment approaches?

Papers that address a clinically relevant liver-disease question with strong evidence will survive triage more reliably than technically sound studies without clear disease implications.

For Hepatology, the useful question is:

Does this study advance liver-disease science in a way that the AASLD community would consider significant?

If yes, the journal is a strong fit. If the paper is a basic science study where the liver connection is peripheral, or a clinical observation without practice-changing implications, the acceptance rate is not the constraint. The disease significance is.

The common misses are:

• centering strategy around an unofficial percentage instead of checking liver-disease significance
• submitting GI work that happens to include liver data without the liver being the central question
• presenting animal model results without connecting them to human liver disease
• ignoring Journal of Hepatology (EASL flagship) as the direct competitor and alternative
• treating Hepatology Communications as a lesser journal rather than a realistic landing spot for sound work

Those are significance and scope problems before they are rate problems.

If you are deciding whether to submit, these pages are more useful than an unofficial rate:

• Hepatology cover letter
• Hepatology submission process
• Hepatology submission guide
• Gastroenterology acceptance rate (for broader GI work)
• Gut acceptance rate (for GI work with liver overlap)

Together, they tell you whether the paper has enough liver-disease significance, whether the editorial timeline is manageable, and whether a different hepatology venue would be a cleaner first submission.

In our pre-submission review work evaluating manuscripts targeting Hepatology, three patterns generate the most consistent desk rejections. Each reflects the journal's standard: liver disease research with the clinical scale, translational depth, or practice-changing significance the AASLD flagship requires.

Study with peripheral liver data rather than a liver-disease scientific question. The AASLD flagship is specifically a hepatology journal, and the editorial filter distinguishes between papers where liver biology is the central scientific subject and papers where liver-related measurements appear because the organ is affected by the primary disease or treatment. The failure pattern is an oncology, metabolic disease, or cardiology paper that includes hepatic biomarkers, liver function tests, or imaging data as safety endpoints or secondary analyses, submitted to Hepatology because the liver data is present. These papers fail triage immediately. A genuine Hepatology paper asks a question about how a liver disease develops, progresses, responds to treatment, or can be prevented, with the liver as the central scientific focus, not as a secondary observation site.

Mechanistic liver disease paper without human tissue validation. Hepatology publishes preclinical and translational liver science, but the AASLD flagship expects a human data tier at submission for mechanistic papers. The failure pattern is a study using diet-induced MASH mouse models, surgical biliary obstruction models, or CCl4-induced fibrosis models to establish a mechanism (a signaling pathway, an immune cell interaction, a fibrogenic mediator), with rigorous genetic and pharmacologic validation in the animal system, followed by a discussion acknowledging that validation in human liver disease tissue is needed for future work. Papers in this category consistently receive desk rejections with feedback that the translational gap prevents acceptance at the flagship level. Authors who add even a modest human tissue analysis, such as pathway activity in a publicly available liver disease expression dataset or immunohistochemistry in a small patient biopsy cohort, substantially improve triage outcomes.

Clinical study below the AASLD flagship evidence threshold. Hepatology's clinical papers are expected to provide evidence at the scale and rigor that clinical guideline committees find actionable. The failure pattern is a single-center observational study with 100-400 patients with MASLD, hepatocellular carcinoma, or chronic viral hepatitis, reporting an association between a clinical variable and disease outcome, with appropriate statistical analysis and a genuine finding, but without the multicenter validation, population generalizability, or study design strength that makes the finding applicable beyond the submitting institution. These papers are redirected to Hepatology Communications, where the scope and selectivity are appropriate to the study scale. A Hepatology submission readiness check can assess whether the study design, sample size, and clinical significance meet Hepatology's threshold before submission.

The honest answer to "what is the Hepatology acceptance rate?" is that AASLD does not publish one, and third-party estimates around 15% should be treated as approximate.

The useful answer is:

• yes, this is the AASLD flagship and a selective liver journal
• no, a guessed percentage is not the right planning tool
• use liver-disease significance, clinical relevance, and AASLD-community importance as the real filter instead

If you want help pressure-testing whether this manuscript is positioned for a Hepatology submission before upload, a Hepatology submission readiness check is the best next step.

The acceptance rate for Hepatology does not distinguish between desk rejections and post-review rejections. A paper desk-rejected in 2 weeks and a paper rejected after 4 months of review both count the same. The rate also does not reveal how acceptance varies by article type, geographic origin, or research area within the journal's scope.

Acceptance rates cannot predict your individual odds. A strong paper with clear scope fit, complete data, and solid methodology has substantially better odds than the headline number suggests. A weak paper with methodology gaps will be rejected regardless of the journal's overall rate.

A Hepatology submission readiness check identifies the specific framing and scope issues that trigger desk rejection before you submit.